Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Tideglusib for the Treatment of Congenital or Childhood Onset DM1 (REACH CDM X)

NCT05004129 is registered in ClinicalTrials.gov with AMO Pharma Limited as lead sponsor.

NCT NCT05004129
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05004129 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Tideglusib for the Treatment of Congenital or Childhood Onset DM1 (REACH CDM X)
Lead sponsor
AMO Pharma Limited
Phase
Phase 2/3
Overall status
Recruiting
Start date
August 23, 2021
Completion date
December 31, 2026
Enrollment
76 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

congenital myotonic dystrophy